News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,041 Results
Type
Article (15924)
Company Profile (43)
Press Release (259064)
Multimedia
Podcasts (25)
Webinars (4)
Section
Business (87468)
Career Advice (686)
Deals (14668)
Drug Delivery (54)
Drug Development (34575)
Employer Resources (72)
FDA (7237)
Job Trends (6181)
News (133317)
Policy (11259)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (3)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (1263)
Academic (1)
Accelerated approval (24)
ADA (20)
Adcomms (16)
Allergies (109)
Alliances (20925)
ALS (113)
Alzheimer's disease (801)
Antibody-drug conjugate (ADC) (192)
Approvals (7610)
Artificial intelligence (293)
ASCO (145)
Autoimmune disease (150)
Automation (39)
Bankruptcy (108)
Belgium (2)
Best Places to Work (4704)
BIO (24)
Biologics (5)
BIOSECURE Act (6)
Biosimilars (134)
BioSpace Insights (47)
Biotechnology (13)
Bladder cancer (84)
Brain cancer (33)
Breast cancer (342)
Cancer (2556)
Cardiovascular disease (264)
Career advice (600)
Career pathing (23)
CAR-T (156)
CDC (33)
CDMO (41)
Celiac Disease (2)
Cell therapy (394)
Cervical cancer (24)
Clinical research (31748)
Collaboration (971)
Commercialization (6)
Company closure (3)
Compensation (326)
Complete response letters (35)
COVID-19 (1230)
CRISPR (50)
C-suite (536)
Cystic fibrosis (66)
Data (4089)
Denatured (11)
Depression (60)
Dermatology (61)
Diabetes (331)
Diagnostics (2744)
Digital health (22)
Diversity (9)
Diversity, equity & inclusion (28)
Drug discovery (161)
Drug pricing (75)
Drug shortages (19)
Duchenne muscular dystrophy (121)
Earnings (26827)
Editorial (34)
Employer branding (7)
Employer resources (68)
Events (38677)
Executive appointments (486)
FDA (9068)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (5)
Frontotemporal dementia (13)
Funding (829)
Gene editing (83)
Generative AI (27)
Gene therapy (291)
GLP-1 (505)
Government (1527)
Grass and pollen (4)
Guidances (184)
Healthcare (8038)
Hematology (84)
HIV (65)
Huntington's disease (22)
IgA nephropathy (51)
Immunology and inflammation (102)
Immuno-oncology (52)
Indications (105)
Infectious disease (1391)
Inflammatory bowel disease (100)
Inflation Reduction Act (7)
Influenza (64)
Intellectual property (98)
Interviews (123)
IPO (5667)
IRA (22)
Job creations (1590)
Job search strategy (505)
JPM (16)
Kidney cancer (13)
Labor market (41)
Layoffs (190)
Leadership (23)
Legal (2272)
Licensing (13)
Liver cancer (43)
Longevity (13)
Lung cancer (280)
Lymphoma (233)
Machine learning (26)
Management (22)
Manufacturing (512)
Marketing (9)
MASH (111)
Medical affairs (1)
Medical device (5917)
Medtech (6015)
Mergers & acquisitions (9664)
Metabolic disorders (767)
mRNA (79)
Multiple sclerosis (114)
NASH (18)
Netherlands (3)
Neurodegenerative disease (185)
Neuropsychiatric disorders (27)
Neuroscience (1550)
NextGen: Class of 2026 (2850)
Non-profit (2080)
Now hiring (21)
Obesity (318)
Opinion (85)
Ovarian cancer (103)
Pain (105)
Pancreatic cancer (111)
Parkinson's disease (224)
Partnered (14)
Patents (158)
Patient recruitment (340)
Peanut (43)
People (25178)
Peptides (2)
Pharmaceutical (20)
Pharmacy benefit managers (14)
Phase 1 (7765)
Phase 2 (13602)
Phase 3 (12443)
Pipeline (4791)
Policy (134)
Postmarket research (1289)
Preclinical (2878)
Press Release (40)
Prostate cancer (157)
Psychedelics (22)
Radiopharmaceuticals (158)
Rare diseases (520)
Real estate (3330)
Recruiting (26)
Regulatory (10034)
Reports (18)
Research institute (1094)
Resumes & cover letters (91)
Rett syndrome (12)
RNA editing (6)
RSV (36)
Schizophrenia (71)
Series A (154)
Series B (112)
Service/supplier (1)
Sickle cell disease (45)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (14)
Startups (1648)
Stomach cancer (7)
Supply chain (55)
Tariffs (22)
The Weekly (14)
Vaccines (516)
Venture capital (52)
Weight loss (204)
Women's health (59)
Worklife (10)
Date
Today (28)
Last 7 days (227)
Last 30 days (858)
Last 365 days (11648)
2026 (8205)
2025 (11461)
2024 (13311)
2023 (15138)
2022 (19801)
2021 (21475)
2020 (21066)
2019 (19768)
2018 (15335)
2017 (13914)
2016 (13297)
2015 (15273)
2014 (10773)
2013 (8590)
2012 (9370)
2011 (9850)
2010 (8471)
Location
Africa (332)
Alabama (74)
Alaska (5)
Arizona (108)
Arkansas (5)
Asia (18549)
Australia (3017)
California (5254)
Canada (1072)
China (704)
Colorado (153)
Connecticut (211)
Delaware (206)
Europe (50085)
Florida (779)
Georgia (211)
Hawaii (1)
Idaho (26)
Illinois (481)
India (75)
Indiana (249)
Iowa (8)
Japan (413)
Kansas (94)
Kentucky (31)
Louisiana (25)
Maine (33)
Maryland (504)
Massachusetts (4175)
Michigan (151)
Minnesota (273)
Mississippi (3)
Missouri (57)
Montana (6)
Nebraska (14)
Nevada (54)
New Hampshire (48)
New Jersey (1506)
New Mexico (9)
New York (1330)
North Carolina (630)
North Dakota (9)
Northern California (2607)
Ohio (192)
Oklahoma (5)
Oregon (10)
Pennsylvania (1103)
Puerto Rico (16)
Rhode Island (6)
South America (485)
South Carolina (14)
Southern California (2221)
Tennessee (91)
Texas (745)
United States (19056)
Utah (167)
Virginia (124)
Washington D.C. (28)
Washington State (437)
West Virginia (3)
Wisconsin (85)
Wyoming (2)
275,041 Results for "emd group emd millipore headquarters".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
Press Releases
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations
July 8, 2026
·
7 min read
Job Trends
Out of sight, out of work? What’s driving remote job cuts
Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.
August 20, 2026
·
4 min read
·
Angela Gabriel
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will cover its flu pill Xofluza.
October 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
November 24, 2025
·
6 min read
Press Releases
EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies
October 17, 2025
·
6 min read
Business
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
November 14, 2023
·
3 min read
Press Releases
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
June 13, 2025
·
8 min read
Press Releases
EMD Serono Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
May 23, 2025
·
19 min read
Press Releases
EMD Serono to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
September 18, 2025
·
19 min read
1 of 27,505
Next
